Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial

摘要: Abstract Objectives: To evaluate whether antistaphylococcal prophylaxis in infants and young children with cystic fibrosis (CF) would suppress the acquisition of Staphylococcus aureus delay onset manifestations bronchopulmonary disease. Study design: A 7-year, multicenter, double-blind, placebo-controlled study continuous therapy. Otherwise healthy Results: Of 209 enrolled, 119 completed a 5- to 7-year course Mean age at enrollment was 15.6 14.1 months cephalexin placebo groups, respectively. Respiratory cultures from treated were significantly less likely be positive for S (6.0% vs 30.4%; P Pseudomonas aeruginosa (25.6% 13.5%; Conclusions: Although long-term successfully delayed , it enhanced colonization did not lead clinically significant improvement major health outcomes. These data do support routine prophylaxisin otherwise CF. (J Pediatr 2002;140:299-305)